A Market That Refuses to Quit
The broader market has staged an impressive and, for many, unexpected rally this week, pushing to all-time highs despite morning selling pressure and the general discomfort of buying into strength at the upper end of the range. The resilience is particularly striking because most forecasts had these index levels being reached far later in the year than April. The ability of equities to recover from intraday weakness and finish higher signals real relative strength and momentum — the kind of breathtaking advance that few observers were calling a month ago, even those who allowed for the possibility of higher prices. Against this backdrop, three names stand out for distinct trade opportunities: a pharmaceutical name finally finding traction, a payments giant emerging from a painful drawdown, and a consumer finance company reversing its recent slide.
Pfizer: A Pullback Within a Recovering Uptrend
After a difficult couple of years, Pfizer has begun to show meaningful relative strength, benefiting from a rotation into healthcare that started last fall. A recent pullback has created what looks like a longer-term entry point for investors willing to hold the stock while generating some yield.
Technically, the stock repeatedly tested resistance in the 27.50 to 27.75 area before breaking out to new highs around 28.75. The subsequent pullback found lows near 26.70, with a rangebound area around 26.35 acting as a floor. The broader structure still shows a series of progressively higher lows and an intact uptrend on the year. Price is currently hanging around the confluence of the 5-day and 21-day exponential moving averages near 27.30, with the 63-day EMA just below at 26.90. The RSI is consistent but unspectacular, sitting just below the 50 midline and showing only a very modest uptrend. The volume profile reveals heavy trading activity between 27 and 27.50, meaning a push above 27.50 could unlock faster-moving prices, while the overall point of control sits much lower at 24.68.
The corresponding trade is a buy-write: purchasing the stock at these reduced levels and selling the June 29 call for roughly 43 cents. That yields about 1.5% versus the stock over 63 days — two expiration cycles — while leaving room to participate in a move back toward the highs. Synthetic yield is the main attraction, with the flexibility to close or roll the position at expiration depending on where the stock sits.
Visa: A Bottom Taking Shape After a Heavy Selloff
Visa has been weighed down year to date, pressured both by broader market rotation and by credit cap-related conversations. Despite its weakness, the stock now appears to be establishing a bottom and reclaiming key technical levels, with a broken downtrend line reinforcing the case that it was thrown out with the bathwater during the recent selloff.
The absolute low came in just below 294 — 293.89 to be precise — with a temporary bottom forming around 295. The downward trend line connecting the highs has been pushed through, and a shorter-term upward-sloping trend line is now in play. Key levels to watch on the downside include 303 as a recent low and 295 as a worst close. To the upside, 321 stands out because old support has become new resistance — that level acted first as a low close during a November decline, then as a subsequent high after the breakdown. Beyond 321 sits 338, followed by 347, which marks the beginning of a gap that would be the next meaningful resistance if momentum accelerates.
Price has crossed above its shorter-term moving averages, with the 5-day EMA diverging from the 21-day — a classic sign of trend change from down to up. The next resistance among moving averages is the 251-day EMA in the 327 area. The RSI has improved, making new relative highs and crossing above the 50 midline, a bullish development. The prior volume area between 302 and 310 has been broken, and the next heavy trading zone sits around 325 to 330.
Because earnings arrive within the trade window, the structure is built to handle volatility. Buying the May 320/335 call spread and selling the May 300 put creates a position that captures upside through the 321 to 335 range while accepting that a drop to roughly 301 — just above the recent lowest close — would result in being put the stock, a level where owning Visa is acceptable. The short put finances the call spread, reducing cost if momentum carries the stock higher through earnings and into May expiration.
Synchrony Financial: Momentum Shifting in a Beaten-Down Name
Synchrony has shown tremendous strength over the years but more recently absorbed heavy selling pressure as financials broadly came under stress. With valuations now more compelling and the trend reversing, the stock looks positioned to continue recovering.
The technical picture illustrates why keeping track of gap levels matters. A prior gap was filled near the 64 level, which is roughly where the stock bottomed. From there, a downward-sloping trend line was broken, and a new, larger upside gap formed between 81 and 87 — a notable target for any continued advance. Another gap near 72, formed after the most recent move higher about a week ago, is the first meaningful support to watch. Price has been traveling in a very tight upward channel, with the 5-day EMA at 74.64 sitting close to the lower channel line, creating a confluence that would signal breakdown if violated. Three longer-term EMAs cluster near the 70 to 71 level, offering a potential safety net. The RSI remains in overbought territory while hugging its trend line — a crossover below 70 would hint at a slowdown. The volume profile shows price on the verge of exiting the heaviest trading zone between 69 and 76, with the point of control near 71.83, and smaller nodes waiting near 80 and 84.
Because Synchrony does not have deep option liquidity, a simple buy-write is the cleanest expression. Owning the stock and writing the June 85 call for about one dollar generates yield over roughly two months, captures the move toward the January highs where resistance is likely, and establishes a natural exit point. If the stock reaches those old highs, the position can be closed for a defined gain, providing a disciplined strategy for a name that is up about 18% in the last month but still down on the year.
A Common Thread
All three ideas share the same underlying logic: identify stocks where momentum has shifted, use technical levels — trend lines, moving averages, gaps, and volume profile — to define entries and exits, and use options to either generate income against long stock or structure asymmetric payoffs through earnings. Buy-writes on Pfizer and Synchrony create synthetic yield in names trending higher, while the call spread and short put combination on Visa leans more aggressively into a recovery thesis with a defined worst-case entry price. In a market running at all-time highs, these structures offer a way to stay engaged without chasing — participating in continued momentum while building in buffers for the inevitable volatility.